Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Haemonetics (NYSE:HAE) from a hold rating to a buy rating in a report published on Saturday.

A number of other analysts also recently weighed in on the stock. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Citigroup reduced their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. BTIG Research restated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday. Finally, JPMorgan Chase & Co. raised their price objective on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $84.10.

Haemonetics Price Performance

Shares of HAE stock opened at $82.01 on Friday. The firm’s 50 day moving average price is $77.66 and its two-hundred day moving average price is $65.92. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The stock has a market cap of $3.84 billion, a PE ratio of 23.98, a PEG ratio of 1.55 and a beta of 0.29.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the prior year, the business posted $1.12 EPS. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Millennium Management LLC lifted its position in Haemonetics by 4,296.3% during the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares in the last quarter. Norges Bank acquired a new position in shares of Haemonetics during the 2nd quarter worth about $36,822,000. Invenomic Capital Management LP grew its holdings in shares of Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares in the last quarter. Finally, SG Capital Management LLC grew its holdings in shares of Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after acquiring an additional 435,660 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Acquisition adds next‑generation large‑bore vascular closure tech (PerQseal Elite), broadening Haemonetics’ product set for structural heart and endovascular procedures. This expansion supports revenue cross‑sell and addresses a growing procedural market. Article Title
• Positive Sentiment: Deal strengthens Haemonetics’ vascular closure market presence and positions it in a niche (sutureless, bioabsorbable closure for up to 26F) that’s relevant to structural‑heart device growth. This is a clear strategic tuck‑in that could accelerate top‑line growth if adoption scales. Article Title
• Positive Sentiment: Analyst and market sentiment supportive: BTIG reaffirmed a “buy” with an $88 price target, signaling incremental analyst confidence that could help investor appetite. Article Title
• Positive Sentiment: Independent research notes Haemonetics’ streak of earnings surprises and suggests the company has the mix to beat again, which can lift sentiment alongside M&A news. Article Title
• Neutral Sentiment: Multiple outlets are reporting the deal and confirming the headline terms (up to €185M), underscoring that the transaction is public and priced; broader market reaction will depend on integration pacing and revenue contribution over time. Article Title
• Negative Sentiment: Potential risks: integration/execution risk and any financing impact (Haemonetics’ balance sheet and leverage could be affected depending on how the deal was funded). These factors could weigh on near‑term margins or sentiment if costs or slower adoption emerge.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.